ReviewJournal of biomedicine & biotechnology2011
Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targets.
Review in Journal of biomedicine & biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Comparative Analysis of the Clinical Manifestations of Sinonasal Natural Killer T-Cell Lymphoma and Diffuse Large B-Cell Lymphoma.Journal of rhinology : official journal of the Korean Rhinologic Society · 2024Article
- Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells.Cancer medicine · 2019Article
- Molecular pathogenic pathways in extranodal NK/T cell lymphoma.Journal of hematology & oncology · 2019Review
- The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.International journal of molecular sciences · 2018Review
- Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas.International journal of hematology · 2018Review
- Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.Annals of hematology · 2017Article
- Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer Panel.Genomics & informatics · 2016Article
- Orphan diseases of the nose and paranasal sinuses: Pathogenesis - clinic - therapy.GMS current topics in otorhinolaryngology, head and neck surgery · 2015Review
- A TNM Staging System for Nasal NK/T-Cell Lymphoma.PloS one · 2015Article
- Controlling distant metastasis and surgical treatment are crucial for improving clinical outcome in uncommon head and neck malignancies, such as non-squamous cell carcinoma.Molecular and clinical oncology · 2014Article
- Primary extranodal NK/T-cell lymphoma of the lung: Mimicking bronchogenic carcinoma.Thoracic cancer · 2014Article
- Non-healing pharyngeal ulcer in a middle-aged Caucasian man.BMJ case reports · 2013Article
- Natural killer cells in healthy and diseased subjects.Journal of biomedicine & biotechnology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal natural killer (NK)/T-cell lymphoma of nasal type (NKTCL) is a malignant disorder of cytotoxic lymphocytes of NK or more rarely T cells associated with clonal Epstein-Barr virus infection. Extranodal NKTCL is rare in Western countries, but in Asia and Central and South America it can account for up to 10% of non-Hodgkin's lymphomas. It is an aggressive neoplasm with very poor prognosis. Although the pathogenesis of extranodal NKTCL remains poorly understood, some insights have been gained in the recent years, especially from genome-wide studies. Based on our own experience and knowledge of the literature, we here review some of the genomic and functional pathway alterations observed in NKTCL that could provide a rationale for the development of innovative therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.